Axsome Therapeutics (AXSM) RBC Capital Markets Global Healthcare Conference 2026 summary

Recent product approval and differentiation

• Received FDA approval for a new indication in Alzheimer's agitation, with a clean label and breakthrough therapy designation.

• Product demonstrates rapid onset and durable treatment effect, with relapse observed upon withdrawal in trials.

• Safety profile is differentiated: no box warning, no mortality or sedation signals, and minimal adverse reactions.

• High unmet need in the indication, with most scripts previously off-label; strong interest from clinicians and KOLs.

• FDA and Alzheimer's Association issued supportive press releases following approval.

Launch preparation and market strategy

• Commercial launch set for June, focusing on sales team training and updated marketing materials.

• Expanding sales force to 630 reps, including new focus on long-term care settings, which represent 40% of scripts.

• High overlap between community and long-term care prescribers for both indications; significant opportunity in long-term care.

• Previous launches in similar settings (e.g., Lexapro) indicate strong potential for growth.

Payer access and competitive positioning

• Expecting 80% of scripts in Medicare Part D, with 100% covered lives and most patients facing minimal prior authorization.

• Commercial coverage for the product has grown to 86% of total covered lives.

• Product positioned for early-line or first-line use due to favorable coverage and differentiated profile.

• Market is large and not zero-sum; multiple products can coexist, with focus on education and patient fit.